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Background: 3-Bromotyrosine (3-BrY) is a stable product of eosinophil peroxidase and may serve as a marker of
eosinophil activation. A gas chromatography/mass spectrometry method to measure 3-BrY concentrations in serum
from dogs has recently been established and analytically validated. The aims of this study were to determine the
stability of 3-BrY in serum, to determine the association between peripheral eosinophil counts and the presence of
an eosinophilic infiltrate in the gastrointestinal tract, and to compare serum 3-BrY concentrations in healthy dogs
(n = 52) and dogs with eosinophilic gastroenteritis (EGE; n = 27), lymphocytic-plasmacytic enteritis (LPE; n = 25),
exocrine pancreatic insufficiency (EPI; n = 26), or pancreatitis (n = 27).
Results: Serum 3-BrY concentrations were stable for up to 8, 30, and 180 days at 4°C, −20°C, and −80°C, respectively.
There was no significant association between peripheral eosinophil count and the presence of eosinophils in the GI
tissues (P = 0.1733). Serum 3-BrY concentrations were significantly higher in dogs with EGE (median [range] = 5.04
[≤0.63-26.26] μmol/L), LPE (median [range] = 3.60 [≤0.63-15.67] μmol/L), and pancreatitis (median [range] = 1.49
[≤0.63-4.46] μmol/L) than in healthy control dogs (median [range] =≤0.63 [≤0.63-1.79] μmol/L; P < 0.0001), whereas
concentrations in dogs with EPI (median [range] = 0.73 [≤0.63-4.59] μmol/L) were not different compared to healthy
control dogs.
Conclusions: The present study revealed that 3-BrY concentrations were stable in serum when refrigerated and
frozen. No relationship between peripheral eosinophil count and the presence of eosinophils infiltration in the
GI tissues was found in this study. In addition, serum 3-BrY concentrations were increased in dogs with EGE, but
also in dogs with LPE and pancreatitis. Further studies are needed to determine whether measurement of 3-BrY
concentrations in serum may be useful to assess patients with suspected or confirmed EGE or LPE.
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Chronic enteropathy (CE) is characterized by recurrent or
persistent gastrointestinal (GI) signs for more than 3 weeks
[1,2]. The diagnostic process for patients with suspected CE
requires exclusion of GI parasites and other extra GI dis-
eases (e.g., pancreatitis, exocrine pancreatic insufficiency
(EPI)). CE is classified by a patient’s response to a given* Correspondence: psatta@cvm.tamu.edu
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article, unless otherwise stated.treatment trial, namely, food-responsive diarrhea,
antibiotic-responsive diarrhea, and steroid-responsive diar-
rhea. The histological findings in dogs with steroid-
responsive diarrhea (idiopathic inflammatory bowel disease;
IBD) differ due to various inflammatory cells within the in-
testinal mucosa. IBD in dogs can thus be subclassified into
eosinophilic gastroenteritis (EGE), lymphocytic-plasmacytic
enteritis (LPE), granulomatous enteritis, and histiocytic
ulcerative colitis [3,4]. In dogs with IBD, the small intestine
is affected more commonly than the large intestine [1].
Clinical scoring systems including the canine chronic enter-
opathy clinical activity index (CCECAI) and the canine IBDd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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severity and treatment response in dogs with IBD [1,5].
Nevertheless, no biomarker for eosinophilic infiltration has
previously been identified in dogs with GI disease.
The defining feature of EGE is infiltration of eosinophils
in the GI tract. EGE can be caused by parasite infestation,
neoplasia, allergy, IBD, or hypereosinophilic syndrome. Al-
though previous studies have reported that the histopatho-
logical findings of GI biopsies would suggest that EGE is
secondary to LPE in canine IBD [6,7], eosinophils were
shown to play crucial roles in stimulating inflammation
and motility, leading to clinical signs such as diarrhea, in-
flammation, tissue destruction, fibrosis formation, and/or
strictures [8,9]. Therefore, a marker of eosinophil activa-
tion may provide a useful tool for evaluating the contribu-
tion of eosinophils in canine CE.
Eosinophil peroxidase (EPO) is a potent granular cyto-
toxic heme-protein released during the activation of eo-
sinophils [10-12]. Under physiological conditions, EPO
utilizes bromide to yield hypobromous acid (HOBr) [13].
Bromination of tyrosine by HOBr in surrounding tissues
and blood occurs rapidly and results in the production
of 3-bromotyrosine (3-BrY) [10-12,14]. Structurally and
physiologically, 3-BrY is a stable product. Therefore, it can
be used as a noninvasive marker of eosinophil-catalyzed
protein oxidation. A method to measure 3-BrY in dog
serum using an electron ionization gas chromatography/
mass spectrometry (EI-GC/MS) has recently been devel-
oped and analytically validated [15].
The hypothesis of this study was that activation of
EPO plays an important role in the pathogenesis of EGE
and serum concentrations of 3-BrY may have diagnostic
potential as a specific biomarker for EGE. The assay may
be particularly useful to differentiate between patients
with EGE and LPE, as well as dogs with other GI dis-
eases. The objectives of this study were (1) to assess the
stability of serum 3-BrY concentrations after storage at
4°C, −20°C, and −80°C, (2) to determine the association
between peripheral eosinophil counts and the presence
of an eosinophilic infiltrate in the GI tract, and (3) to
compare serum 3-BrY concentrations between healthy
control dogs and dogs with various GI diseases, such as
EGE, LPE, EPI, and pancreatitis.
Methods
Determination of stability for 3-BrY in serum samples
Excess serum samples that were submitted to the Gastro-
intestinal Laboratory (GI Lab) at Texas A&M University
for diagnostic purposes were pooled. Known quantities of
pure 3-BrY (BOC Science Company, Shirley, NY) were
mixed to pool serum samples to obtain 10 different 3-BrY
concentrations within the working range of the 3-BrY
assay (0–50 μmol/L). On day 0, samples were prepared,
divided into aliquots, and stored at 4°C, −20°C, or −80°Cuntil analysis. Serum 3-BrY concentrations were deter-
mined on days 0, 2, 8, 16, 30, 60, and 180. On day 0, sam-
ples were analyzed immediately after they were prepared.
Serum samples stored at 4°C were analyzed on days 2 and
8. Serum samples stored at −20°C were analyzed on days
8, 16, 30, and 60. Finally, serum samples stored at −80°C
were analyzed on days 16, 30, 60, and 180.
Determination of the association between peripheral
eosinophil counts and the presence of an eosinophilic
infiltrate in the gastrointestinal tract
Peripheral eosinophil counts were records in dogs with
EGE and dogs with LPE. 25 dogs with EGE were en-
rolled based on the presence of eosinophilic infiltrates in
GI biopsy specimens. 23 dogs with LPE were enrolled
based on the presence of lymphocytes and plasma cells
infiltrate in GI biopsy specimens.
Comparison of serum 3-BrY concentrations between
healthy control dogs and dogs with various
gastrointestinal diseases
Samples from healthy control dogs
Serum samples from 52 healthy control dogs were col-
lected. The sample collection protocol was approved by
the Texas A&M University Institutional Animal Care and
Use Committee (#2012-101), and informed owner consent
was obtained for all dogs. None of the healthy dogs did
manifest any clinical or laboratory abnormalities and re-
ceived regular vaccinations and deworming.
Samples from dogs with EGE
Surplus canine serum samples from submissions to the
GI Lab at Texas A&M University from 27 dogs with
EGE were used for this study. The diagnosis was based
on the presence of eosinophilic infiltrates in GI biopsy
specimens. All patients had serum cPLI and cTLI con-
centrations within the reference interval.
Samples from dogs with LPE
Surplus canine serum samples from submissions to the
GI Lab at Texas A&M University from 25 dogs with
LPE were used. The diagnosis of LPE was based on the
presence of lymphocytes and plasma cells with an ab-
sence of eosinophils in the GI mucosa during histo-
logical evaluation of GI biopsies. All patients had serum
cPLI and cTLI concentrations within the reference
interval.
Samples from dogs with EPI
Surplus canine serum samples from submissions to the
GI Lab at Texas A&M University from 26 dogs with a
serum canine trypsine like immunoreactivity (cTLI)
concentration ≤2.5 μg/L were used. All of these sam-
ples showed a normal serum canine pancreatic lipase
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detectable serum cobalamin concentration ≤149 ng/L.
Samples from dogs with pancreatitis
Surplus canine serum samples from submissions to the GI
Lab at Texas A&M University from 27 dogs with a serum
cPLI concentration ≥1001 μg/L were used. It should be
noted that the suggested diagnostic cut-off value of serum
cPLI concentration for a diagnosis of pancreatitis is >400 μg/
L. Also, all patients had serum cobalamin and cTLI con-
centrations within the respective reference interval.
Samples from dogs with CE
Dogs with CE comprised of 25 dogs with LPE and 27
dogs with EGE.
All serum samples were stored at −80°C for up to
6 months until analysis. Population demographics for
dogs enrolled in this study are shown in Table 1. Stand-
ard questionnaires were sent out to the primary care vet-
erinarian to obtain histories, clinical signs at the time of
sample collection, and the final diagnosis. Question-
naires for 25 (92.6%) dogs with EGE, 23 (92.0%) dogs
with LPE, 14 (53.8%) dogs with EPI, and 15 (55.6%) dogs
with pancreatitis were completed by the primary care
veterinarian. The clinical diagnosis for each dog was
based on the result of the histological evaluation of GI
biopsies or clinical laboratory data such as cTLI and
cPLI. The tissues that had been evaluated for the pur-
pose of this study included stomach, duodenum, ileum,
and colon. However, there was no uniformity as to the
sample type evaluated in all patients. Also, left-over
serum samples were used from dogs with histopatho-
logical reports to indicate the presence of either LPE or
EGE.
Measurement of serum 3-BrY
Preparation of internal standards
D3-bromotyrosine (D3-BrY) was used as an internal stand-
ard and prepared by reacting d4-L-tyrosine (CambridgeTable 1 Population demographics for dogs enrolled in this st
Healthy dogs EGE
Number of dogs 52 27
Age* (years) 4.0 (1–10) 5.0 (<1-12)
Sex
Male 61.5% (n = 32) 44.4% (n = 12)
Female 39.2% (n = 20) 55.6% (n = 15)
Breed sizes
Small (<10 kg) 23.1% (n = 12) 18.6% (n = 5)
Medium (10–20 kg) 42.3% (n = 22) 33.3% (n = 9)
Large (>20 kg) 34.6% (n = 18) 48.1% (n = 13%)
*Median (minimum to maximum range).Isotope Laboratories, Inc., Tewksbury, MA) with N-
bromosuccinimide (Sigma-Aldrich, St. Louis, MO) in
water [12,16,17]. D3-BrY was isolated by reverse-phase
high performance liquid chromatography (HPLC) using
a C18 HPLC column (Phenomenex, Torrance, CA).
Purified D3-BrY fractions were collected and stored
at −80°C under helium until use.
Measurement of 3-BrY in canine serum
The sample preparation protocol was adapted from previ-
ous publications [10,16,18]. Eight nanomoles (16 μmol/L)
of D3-BrY were added in a 1 to 2 dilution mixture of water
(250 μl) and serum sample (250 μl). The volume of the
mixture was adjusted to 2 mL with 0.1% trifluoroacetic
acid (Sigma-Aldrich, St. Louis, MO), pH5.0 and centri-
fuged at 4°C for 10 min at 16,000 × g. After centrifugation,
the mixture was passed through a C18 solid phase extrac-
tion column (Sigma-Aldrich Company, St. Louis, MO). 3-
BrY was eluted from the column with 25% methanol
(Sigma-Aldrich, St. Louis, MO) in water. The eluent was
immediately dried in a rotary vacuum device (Eppendorf,
Hauppauge, NY) at 45°C and stored at −80°C until further
analysis.
The derivatization protocol was modified from protocols
described previously [10,16,18]. The previously dried sam-
ple was mixed with 100 μL of acetonitrile (Thermo Fisher
Scientific, Inc., Pittsburgh, PA) and 40 μL of diisopropy-
lethylamine (Sigma-Aldrich, St. Louis, MO). The sample
was incubated on ice for 5 min. Ethyl heptafluorobutyrate
(Sigma-Aldrich, St. Louis, MO) was added into the sample
and the sample underwent an incubation period for
30 min on ice. Then, the sample was sonicated in a
water bath for 1 h at room temperature. Excess reagents
were evaporated under a nitrogen stream at room tem-
perature. Thirty μL of N-methyl-N-(t-butyldimethylsilyl)-
trifluoroacetamide (MtBSTFA) (Thermo Fisher Scientific,
Inc., Pittsburgh, PA) was added to the sample followed by
30 min incubation at room temperature. The sample was
completely dried under a nitrogen stream and redissolvedudy
LPE EPI Pancreatitis
25 26 27
8.5 (2–12) 5.8 (1–16) 11.0 (<1-16)
52.0% (n = 13) 42.3% (n = 11) 48.1% (n = 13)
48.0% (n = 12) 57.7%(n = 15) 52.9% (n = 14)
56.0% (n = 14) 23.1% (n = 6) 59.3% (n = 16)
20.0% (n = 5) 23.1% (n = 6) 7.4% (n = 2)
24.0% (n = 6) 53.8% (n = 14) 33.3% (n = 9)
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taining 25% (v/v) MtBSTFA. One μL of the clear superna-
tants were analyzed immediately by EI-GC/MS.
An Agilent 7890A gas chromatography (Agilent
Technologies, Santa Clara, CA) and a 5975C mass de-
tector (Agilent Technologies, Santa Clara, CA) were used
to measure 3-BrY concentrations. A capillary column
(Agilent Technologies, Santa Clara, CA) was used to sep-
arate the analytes using helium as a carrier gas. The in-
jector, transfer line, and source temperature were initially
set at 180°C, 300°C, and 250°C, respectively. The oven
temperature gradient was increased at a rate of 40°C/min
from 180°C to 310°C. Ions were monitored at m/z 257 and
259 for 3-BrY and D3-BrY, respectively.
Statistical methods
All statistical analyses were performed with commercial
software packages, JMPPro 10 (SAS Institute Inc., Cary,
NC) or GraphPad PRISM5.0 (GraphPad software, Inc. La
Jolla, CA). Each data set was tested for normality using a
Shapiro-Wilk’s test. To evaluate stability, serum 3-BrY
concentrations for fresh samples and samples at each of
the 3 temperatures (4°C, −20°C, and −80°C) were com-
pared using repeated measures ANOVA. The Dunn’s
post-test was used to determine the differences in serum
3-BrY concentrations at different time points under the
same storage temperature. In addition, the coefficient of
variation (%CV = [standard deviation/mean] × 100) was
used to determine the variability of serum 3-BrY concen-
tration under each storage condition.
A Fisher’s exact test was used to determine the associ-
ation between peripheral eosinophil count and the pres-
ence of eosinophils in the GI tract in dogs with EGE and
dogs with LPE. A Kruskal-Wallis test was used to evalu-
ate the difference of serum 3-BrY concentrations be-
tween healthy dogs and dogs with various GI diseases.
The Dunn’s post-test was applied to determine differ-
ences between groups. The Mann–Whitney U test wasFigure 1 Stability of serum 3-BrY concentration for each storage tem
stable at 4°C for up to 7 days (%CV≤ 8.5, P > 0.05), at −20 up to 30 days (%
However, 3-BrY concentrations were not stable at −20°C at 60 days (%CV≤used to determine the differences between dogs with CE
and healthy control dogs. For all analytical tests, signifi-
cance was set at P < 0.05.
Results
No significant differences were found between the mean
serum 3-BrY concentrations for 10 individual samples
stored at 4°C, −20°C, or −80°C for ≤8 days, ≤30 days, or
≤180 days, respectively (Figure 1). However, the Dunn’s
post test showed that 3-BrY was not stable after 60 days
at −20°C (P = 0.0018). The mean and %CV for each sam-
ple in each storage condition were displayed in Table 2.
There was no significant association between periph-
eral eosinophil count and the presence of eosinophils in
the GI tissues (P = 0.1733; Figure 2). In healthy dogs, the
median serum 3-BrY concentration was ≤0.63 μmol/L
with a range of ≤0.63 to 1.79 μmol/L. The median
[range] of serum 3-BrY concentrations in dogs with
EGE, LPE, EPI, and pancreatitis were 5.04 [≤0.63-26.26],
3.60 [≤0.63-15.67], 0.73 [≤0.63-4.59], and 1.49 [≤0.63–
4.46] μmol/L, respectively. There was a statistically sig-
nificant difference in serum 3-BrY concentrations be-
tween dogs with EPI, pancreatitis, LPE, EGE, and
healthy dogs (P < 0.0001; Figure 3). The Dunn’s post-test
analysis revealed differences of serum 3-BrY concentra-
tions between healthy control dogs and dogs with either
EGE, LPE, or pancreatitis. Serum concentrations of 3-
BrY were significantly higher in dogs with EGE than in
healthy dogs (P < 0.0001) or dogs with EPI (P = 0.0072).
Also, serum 3-BrY concentrations were significantly
higher in dogs with LPE than those in healthy dogs (P <
0.0001) or dogs with EPI (P = 0.0039). Serum 3-BrY con-
centrations were significantly higher in dogs with pan-
creatitis than in healthy dogs (P < 0.0135). However,
there was no statistically significant difference of serum
3-BrY concentrations between dogs with EGE and LPE
(P = 1.0000). Finally, Serum 3-BrY concentrations were
significantly higher in dogs with CE (median [range]:perature. When compared to fresh samples, 3-BrY concentrations were
CV≤ 15.8, P > 0.05 ), and at −80°C up to 180 days (%CV≤ 9.9, P > 0.05).
30.3, P = 0.0018).
Table 2 Mean and %CV of 3-BrY concentrations for each
pooled canine serum sample (n = 10) when measured
fresh or stored under different storage conditions (4°C
for 7 days, −20°C for 60 days, and −80°C for 180 days)
Sample Mean 3-BrY ± SD
(μmol/L)
%CV
Fresh and
4°C
Fresh and
−20°C
Fresh and
−80°C
1 3.9 ± 1.3 8.5 14.4 9.1
2 4.7 ± 0.6 7.9 2.0 6.6
3 7.4 ± 1.4 3.0 14.8 4.2
4 7.6 ± 1.4 2.9 24.2 9.9
5 9.7 ± 0.9 4.0 30.3 6.3
6 10.3 ± 1.0 6.6 9.6 3.9
7 13.9 ± 1.5 3.5 13.3 4.3
8 15.5 ± 1.2 2.2 10.9 3.5
9 17.8 ± 0.8 3.6 3.5 4.3
10 19.8 ± 1.6 3.3 5.5 4.9
Figure 3 Serum 3-BrY concentrations in healthy dogs (n = 41),
dogs with EGE (n = 27), LPE (n = 25), EPI (n = 26), or pancreatitis
(n = 27). The medians of serum 3-BrY concentrations are shown in
dashed lines. Columns not sharing a common superscript are significantly
different (P< 0.05).
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0.0001; Figure 4).
Discussion
The stability of 3-BrY concentrations in serum was eval-
uated in the present study because serum 3-BrY concen-
tration may be affected by storage conditions. The
results from this study suggest that 3-BrY serum con-
centrations are stable when stored at 4°C for ≤8 days,
at −20°C for ≤30 days, and at −80°C for ≤180 days.
Therefore, shipping and storage conditions require
careful consideration.Figure 2 Scatter plot of peripheral eosinophil counts in dogs
with EGE compared to dogs with LPE. There was no association
between peripheral eosinophil counts and eosinophils infiltration in
the GI tissues (P = 0.1733). The medians of peripheral eosinophil
counts for dogs with EGE and LPE were 751 and 520 cell/μl,
respectively (dashed lines). The horizontal solid line represents the
upper limit of peripheral eosinophil.Serum 3-BrY concentrations were slightly altered on
day 8 when stored at 4°C and day 60 when stored
at −80°C; however, this difference was not statistically
significant, suggesting that these findings might also
have been due to inter-assay variation. The %CV for
inter-assay variation of serum 3-BrY concentration has
previously been reported as ≤11.0% [15], whereas the %
CVs for the storage conditions at 4°C and −80°C were ≤8.5
and 9.9%, respectively. Thus, we concluded that the alter-
ations of serum 3-BrY concentrations in samples stored at
4°C and −80°C were most likely an effect of inter-assay
variation.Figure 4 Scatter plot of serum 3-BrY concentrations in 52
healthy dogs and 52 dogs with CE. The medians for 3-BrY
concentration are shown in dashed lines.
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that serum samples were pooled and a known concen-
tration of 3-BrY had been added due to the fact that not
enough serum with higher serum 3-BrY concentrations
were available. Therefore, a known concentration of 3-
BrY was added to each serum sample to reach the quan-
tification limit where 3-BrY was detectable in all serum
samples.
This study provides the first clinical evaluation of
serum 3-BrY concentrations in dogs with GI diseases.
No relationship between peripheral eosinophil count
and the presence of eosinophils infiltration in the GI tis-
sues was found in this study. This finding may be ex-
plained by the fact that eosinophils predominantly reside
in the tissue instead of circulating in the blood stream.
Therefore, peripheral eosinophils count are not always
associated with eosinophil activation in the GI tissues
[19,20]. Thus, the peripheral eosinophil count should
not be considered as a minimally invasive marker for eo-
sinophil activation in dogs with GI disease.
Lymphocytes and neutrophils have been reported as
the predominant inflammatory cells present in dogs with
pancreatitis [21]. In this study, serum 3-BrY concentra-
tions were significantly increased in dogs with pancrea-
titis compared to healthy dogs. This was an unexpected
finding, suggesting eosinophil activation in dogs with
pancreatitis. This may suggest that pancreatic proteases
are released and activate protease-activated receptor-2,
which plays a role in the inflammatory pathway and acti-
vates eosinophils [22-24].
Our findings revealed a significant increase of serum
3-BrY in dogs with LPE and EGE, suggesting an import-
ant pathophysiological role of eosinophil activation in
dogs with these two forms of CE. Serum 3-BrY concen-
trations for both dogs with EGE or LPE were statistically
significantly different from healthy dogs. Although the
median 3-BrY concentration in dogs with EGE was
higher than in dogs with LPE, there was no statistically
significant difference between these two groups. These
findings suggest the presence of eosinophil activation in
the GI tract of dogs with LPE or EGE. However, a larger
sample set may have been needed to determine a pos-
sible difference in serum 3-BrY concentrations between
dogs with EGE and those with LPE.
The presence of eosinophilic infiltration in the GI tract
in dogs with EGE supports the hypothesis that 3-BrY may
serve as a potential biomarker for eosinophil activation.
Our findings are the first to demonstrate that 3-BrY, a
stable product of eosinophilic peroxidase, can be detected
in serum samples from dogs with chronic GI disease.
Other studies in humans and mice have revealed the im-
portant pathophysiological role of EPO in affected GI tis-
sues [25,26]. The lack of CCECAI and CIBDAI scores due
to the use of left-over serum samples precluded us toidentify the relationship between the severity of clinical
signs and serum 3-BrY concentrations. Therefore, further
investigations of the relationship between serum 3-BrY
concentration and the severity of clinical signs are needed
and underway.
One limitation of this study was that the tissue samples
were evaluated by different pathologists from multiple
diagnostic centers in the USA. Therefore, variations in
histopathology scoring between pathologists may exist.
Consequentially, the relationship between the degree of
inflammatory cell infiltration in the GI tract and serum 3-
BrY concentrations could not be performed. It should also
be noted that mild to moderate eosinophilic infiltration
may be present on biopsies in dogs with LPE. More stud-
ies are needed to identify the association between the
grading of eosinophilic infiltration of the GI tract of dogs
with CE and serum 3-BrY concentrations.
The increased serum 3-BrY concentration in dogs with
LPE was an unexpected finding in the present study.
Lymphocytes and plasma cells play a central role in dogs
with LPE. The increased concentration of serum 3-BrY
in LPE may be the result of eosinophil activation stimu-
lated by T-lymphocytes in dogs with chronic GI disease.
It is known that T-lymphocytes secrete IL-5, which is a
key mediator to moderate the maturation, migration,
and activation of eosinophils [27,28]. Moreover, eosino-
phil infiltration may be overlooked during the assess-
ment in the different compartments (i.e., duodenum,
jejunum, ileum, or colon) of the GI tract and this may
lead to the failure to detect the eosinophil infiltration in
those tissues. In addition, the use of hematoxylin and
eosin (H&E) stain may have led to failure to detect eo-
sinophil activation [29,30] when compared to other
methods such as immunohistochemical staining (e.g.,
EPO antibody). However, measurements of 3-BrY con-
centration were performed in serum samples for this
study, which may not accurately characterize inflamma-
tion in the GI tract. Therefore, the development and
analytical validation of this assay for the measurement of
3-BrY concentration in fecal samples is warranted and
underway.
Conclusions
This is the first study that measured serum 3-BrY con-
centrations in dogs with various GI diseases. Our results
suggest that eosinophil activation occurs in dogs with
EGE, LPE, or pancreatitis. The present study also sug-
gests that measurement of serum 3-BrY concentration
may serve as a potential diagnostic marker for dogs with
CE.
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